Regencell Bioscience Holdings Limited
RGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeRegencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Market Cap
—
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.01
EPS (Fwd)
—
ROE
-177.7%
ROA
-85.0%
Cash
$2.4M
Total Debt
$386,302
Free CF
—
52W Change
-48.2%
Annual Financials
Cash vs Debt
Where RGC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RGC finished 67.12% below its 150-day moving average ($19.19) and 68.42% below its 200-day moving average ($19.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGC overbought or oversold?
At the September 3, 2026 close, RGC's RSI(14) was 71.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Regencell Bioscience Holdings Limited holds $2.4M in cash against $386K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. ROE of -177.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, RGC has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing RGC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.